In our 2022 U.S. Pricing Transparency Report, we reported a 3.5% decline in net prices for their medicines, marking the sixth consecutive year of such reductions. Despite providing $39 billion in rebates, discounts and fees to various healthcare entities, this report expresses our concern that patients are not directly benefiting from these lower net prices due to issues like underinsurance and insurance benefit designs.
View the full report here.
All figures according to Johnson & Johnson internal financial accounting. Figures have been rounded.